You are here: Industry Insights > Cidara

News List

Cidara Therapeutics Provides Leadership Update firstwordpharma
July 02, 2021
Cidara Therapeutics, Inc. (NASDAQ: CDTX) today announced that James (Jamie) Levine has resigned from his position as chief financial officer (CFO), effective July 9, 2021, to pursue other opportunities.
Cidara Therapeutics signs deal with Janssen for antiviral conjugates to prevent, treat influenza expresspharma
April 06, 2021
Cidara Therapeutics announced that it has entered into an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals to develop and commercialise Cidara’s Cloudbreak antiviral conjugates (AVCs) for the prevention and ...
Mundipharma and Cidara’s rezafungin gets Orphan Drug Designation in EU pharmaceutical-technology
January 28, 2021
The European Commission (EC) has adopted the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) recommendation to grant Orphan Drug Designation (ODD) to Mundipharma and Cidara Therapeutics’ rezafungin for treating ...
Cidara and Mundipharma sign rezafungin drug development deal pharmaceutical-technology
September 05, 2019
US-based biotech Cidara Therapeutics has partnered with UK-based Mundipharma in a deal valued at more than $568m to develop and commercialise its anti-fungal drug rezafungin.
Mundipharma, Cidara ink $568M deal for antifungal treatment biospectrumasia
September 04, 2019
Collaboration combines strengths to develop and commercialize life-saving antifungal treatment and prophylaxis, an area of high unmet medical need
Cidara Touts Positive Phase II Antifungal Data biospace
March 20, 2018
Shares of Cidara Therapeutics have fallen more than 22 percent this morning despite the company reporting its mid-stage antifungal candidate hit its primary endpoints and is on track to begin Phase III testing later this year.